Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in Multiple Sclerosis

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Inflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• RRMS diagnosis, as Polman et al 2011. Ann Neurol. PMID: 21387374

• Age \<= 18 and =\> 65 years

• EDSS score \<= 7

• Disease duration \< 10 years

• On DMF or Ocrelizumab treatment from at least 3 months

• No corticosteroid administration in the previous month

• Ability to provide written informed consent.

Locations
Other Locations
Italy
IRCCS INM-Neuromed
RECRUITING
Pozzilli
Contact Information
Primary
Silvia Caioli, MD
silviacaioli@yahoo.it
+39 3332790061
Backup
Diego Centonze, MD
centonze@uniroma2.it
+39 3934444159
Time Frame
Start Date: 2023-07-26
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 100
Treatments
Experimental: Pre-Pro group
Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will recieve the following dietary supplementation with pre- and probiotics:~1st-15th days: One capsule containg 6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM® (Probactiol Duo cps, Metagenics) One packet with 4 g of prebiotics including inulin enriched with oligofructose (Probactiol Stips bustine Metagenics).~16th-365th days:~Two capsules, each containg 7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose (Probactiol HMO Combi cps, Metagenics).
Placebo_comparator: Placebo group
Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will receive only starch, the probiotic bacteria carrier:~1st-15th days: One capsule and one packet only with starch.~16th-365th days: Two capsules containg starch.
Related Therapeutic Areas
Sponsors
Leads: Neuromed IRCCS
Collaborators: I.R.C.C.S. Fondazione Santa Lucia

This content was sourced from clinicaltrials.gov